CAMBRIDGE, Mass., Oct. 26, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) announced today that it will report its financial results for the third quarter of 2011 on Wednesday, November 2, 2011 after U.S. financial markets close.
Idenix management will host a conference call at 4:30 p.m. ET on Wednesday, November 2, 2011 to discuss the company’s financial results for the third quarter of 2011 and provide an update on the company’s development programs.
To access the call please dial (877) 640-9809 U.S./Canada or (914) 495-8528 International and enter passcode 22292830. There will also be a slide presentation available to accompany the conference call, which can be accessed on our website in the Idenix Investor Center at www.idenix.com. To listen to a live webcast of the call, go to “Calendar of Events” in the Idenix Investor Center at www.idenix.com. Please log in approximately 10 minutes before the call to ensure a timely connection. A replay of the conference call and webcast will be available until November 16, 2011. To access the replay, please dial (855) 859-2056 U.S./Canada or (404) 537-3406 International and enter the passcode 22292830.
American Association for the Study of Liver Diseases Meeting (AASLD)
Idenix will present two posters at AASLD in San Francisco, California:
- McCarville, et al, “Patterns of NS5B mutations in a 3-day clinical trial of HCV non-nucleoside polymerase inhibitor IDX375" will be presented in a poster session on November 5, 2011 starting at 2:00pm PT
- McCarville, et al, “In vivo resistance profile of IDX320 after 3 days of dosing in genotype 1 HCV-infected patients” will be presented in a poster session on November 5, 2011 starting at 2:00pm PT
About Idenix
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix’s current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to http://www.idenix.com.
Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033 (media)
Eric Hoffman (617) 224-4485 (investors)
SOURCE Idenix Pharmaceuticals, Inc.
